Document:

<PAGE>

                                                                   EXHIBIT 10.30

                                            ***TEXT OMITTED AND FILED SEPARATELY
                                                CONFIDENTIAL TREATMENT REQUESTED
                                           UNDER 17 C.F.R. SECTIONS 200.80(b)(4)
                                                                   AND 240.24B-2

         THIS AGREEMENT is made the Twelfth day of July, One thousand nine
hundred and eighty four between THE WELSH NATIONAL SCHOOL OF MEDICINE whose
principal office is situate at Heath Road Cardiff Wales CF4 4XN (hereinafter
called "WNSM" which expression shall include its successors and assigns) of the
one part and BIOANALYSIS LIMITED whose registered office is situate at College
Buildings Courtenay Road Splott Cardiff (hereinafter called "BIOANALYSIS") of
the other part

                                     WHEREAS

         A.       WNSM has developed techniques for the measurement of the
presence of antibodies binding proteins and other analytes based upon the
phenomenon of chemiluminescence which it believes may be applicable to
immunoassay binding protein and other assay systems (hereinafter called the
"CHEMILUMINESCENCE TECHNOLOGY")

         B.       WNSM is the registered proprietor of the patents particulars
of which are set out in the first part of the Schedule hereto and is entitled to
the benefit of the applications for the patents particulars of which are set out
in the second part of the said schedule

         C.       Bioanalysis has assisted in the development of the techniques
referred to in Recital (A) above and has a number of commercial contacts who
would be interested in manufacturing and marketing clinical diagnostic kits
components for such kits and other related products on a commercial scale and is
also interested in manufacturing and marketing such kits and other products
itself

         D.       WNSM has agreed to grant to Bioanalysis under the said patents
under any patents to be granted under the said applications and under any
further patents to be granted to WNSM relating to the Chemiluminescence
Technology (hereinafter called the "PATENTS") the right and licence either by
itself or with others to develop the Chemiluminescence Technology and to market
and sell either by itself or with others clinical diagnostic kits and/or
components thereof and/or other related products incorporating the
Chemiluminescence Technology upon the terms and conditions hereinafter set forth

         NOW IT IS HEREBY AGREED by and between the parties hereto as follows:

1.       This Agreement shall be deemed to come into force on the Twelfth day of
July One thousand nine hundred and eighty four and shall be read and construed
accordingly

2.       In consideration of the royalties hereinafter reserved and the
covenants on behalf of Bioanalysis hereinafter contained WNSM hereby grants to
Bioanalysis an exclusive right and licence to develop manufacture market and
sell either by itself or with such other parties as Bioanalysis and WNSM shall
determine clinical diagnostic kits and/or components thereof and/or any other
related products incorporating the Chemiluminescence Technology covered by the
Patents

3.       Bioanalysis shall on demand contribute one half of the costs incurred
by WNSM in maintaining in force any of the Patents or applying for further
patents in connection with the Chemiluminescence Technology provided that
nothing in this Agreement shall prevent

                                       1.

<PAGE>

Bioanalysis or its sub-licensees from applying for patents for new techniques or
products not covered by the Patents and for which Bioanalysis or its
sub-licensee are responsible

4.       WNSM represents to Bioanalysis that (i) it is the owner of the Patents
and of all the know-how and information to be disclosed hereunder (ii) it has
not previously granted any rights or licences under the Patents or in connection
with the know-how and information to be disclosed hereunder relating to the
Chemiluminescence Technology to any third parties and (iii) it has power to
grant the rights and licences of this Agreement without any prior or conflicting
obligations whatsoever

5.       Bioanalysis shall not assign transfer mortgage charge or part with any
of its rights duties or obligations under this Agreement but may with the
approval of WNSM grant licences to commercial organisations with a view to the
commercial exploitation of the Chemiluminescence Technology covered by the
Patents for the benefit of WNSM and Bioanalysis In the event that Bioanalysis
does grant licences as aforesaid it shall within One month of the grant of any
such licence furnish to WNSM a true copy thereof

6.       WNSM will on the execution of this Agreement furnish Bioanalysis with
all the information relating to the Patents and the Chemiluminescence Technology
and will from time to time thereafter during the continuance of this Agreement
furnish such further information as may be necessary to keep the same up to date

7.       Each of WNSM and Bioanalysis shall during the continuance of this
Agreement forthwith disclose to the other full details of all improvements in
the Chemiluminescence Technology covered by the Patents which it or any
sub-licensee of Bioanalysis may make or discover during such continuance and the
use of such improvements by WNSM or Bioanalysis shall not give rise to any
liability for payment of any further royalties over and above those payable
hereunder

8.       Bioanalysis shall have the right during the continuance of this
Agreement at its own expense to send its employees to WNSM's laboratories and
workshops and WNSM shall permit such employees to study at reasonable times and
in a reasonable manner the methods processes designs and techniques employed by
WNSM in the development of the Chemiluminescence Technology covered by the
Patents. Bioanalysis shall indemnify and hold WNSM harmless against all loss and
damage claims demands costs or expenses arising out of the acts or omissions of
the employees of Bioanalysis in or about the premises of WNSM in connection with
such arrangements and for this express purpose Bioanalysis shall arrange
appropriate insurance cover with a reputable insurance company

9.       (1) WNSM or Bioanalysis shall not during the continuance of this
Agreement or at any time thereafter disclose any part of the know-how techniques
data or other confidential information relating to the development of the
Chemiluminescence Technology covered by the Patents other than to a sub-licensee
of Bioanalysis and shall treat the same as confidential and to this end shall
cause its directors employees and agents to keep the same in confidence and not
to use or disclose the same except for the purposes of this Agreement

                                       2.

<PAGE>

         (2)      The provisions of this clause shall not apply to such of the
know-how relating to the Chemiluminescence Technology as shall have become
available to the public otherwise than through this Agreement

10.      Bioanalysis shall during the continuance of this Agreement pay to WNSM
a royalty at the rate of [...***...] of the net selling price of each of the
clinical diagnostic kits OR components thereof or other related products
incorporating the Chemiluminescence Technology (hereinafter called the "LICENSED
PRODUCTS") manufactured and sold by Bioanalysis alone and [...***...] of the
royalties received by Bioanalysis on licensed products manufactured and sold by
a sub-licensee of Bioanalysis

11.      Bioanalysis shall during the continuance of this Agreement use its
reasonable endeavours to promote the sale of the licensed products and to obtain
the best market price therefor

12.      Bioanalysis shall keep true and detailed records of all royalties
payable hereunder and shall within Thirty days after the last day of June and
December in each year during which this Agreement shall remain in full force
deliver to WNSM a true account thereof in respect of the preceding half year (or
any part thereof) up to the end of the last preceding June or December as the
case may be showing separately the numbers of the licensed products sold by
Bioanalysis or its sub-licensee and shall at the same time pay to WNSM the
amount of such royalties as may be shown to be due hereunder Provided that if
this Agreement shall terminate otherwise than at the end of June or December in
any year the last account and payment under this Agreement shall be rendered and
made respectively within Thirty days after the termination of this Agreement

13.      Bioanalysis shall permit any duly authorised representative of WNSM
such access to the accounts records of Bioanalysis as shall be reasonably
necessary to verify the accounts rendered under Clause 12 hereof and the
provisions of this Clause shall remain operative (notwithstanding the
determination of this Agreement) until the settlement of all subsisting claims
of WNSM hereunder

14.      Unless terminated as hereinafter provided this Agreement shall continue
in force until the expiry or the last to expire of the Patents

15.      Bioanalysis shall have the right to determine this Agreement at any
time upon giving to WNSM six months' previous notice in writing to that effect

16.      WNSM shall have the right to determine this Agreement forthwith at any
time by notice in writing to Bioanalysis upon the happening of any of the
following events:-

         (a)      if any royalty payable hereunder is in arrears for sixty days
after the same shall have become payable

         (b)      if Bioanalysis shall commit a material breach of any of the
obligations on its part to be performed or observed herein and in the case of a
breach capable of rectification shall fail to rectify the same within thirty
days after notice is given to it by WNSM requiring such remedy

                                               *CONFIDENTIAL TREATMENT REQUESTED

                                       3.

<PAGE>

         (c)      if Bioanalysis has a receiver or manager appointed to the
whole or any substantial part of its assets or if an order shall be made or
resolution passed for the winding up of Bioanalysis unless such order or
resolution is part of a scheme of reconstruction of Bioanalysis

17.      Notwithstanding the failure of either party to exercise any right
hereunder including the right to terminate such failure shall not be deemed a
waiver of such right in any continuing or subsequent default

18.      (1) Bioanalysis shall give notice in writing to WNSM (with full
technical supporting information) of any infringement or threatened infringement
of the Patents which shall at any time and from time to time come to its
knowledge

         (2) If WNSM shall fail for a period of three months after due notice in
writing has been given to WNSM of an infringement of the Patents to institute
proceedings necessary to prevent such infringement and to indemnify Bioanalysis
against all damages claims costs and expenses in respect thereof Bioanalysis
shall be relieved from further obligation to pay any royalties under this
Agreement and shall be at liberty at its own cost to institute and prosecute any
such action or proceedings in the name of WNSM Provided that if the infringement
or alleged infringement shall subsequently cease royalties shall become payable
again as from the date of such cessation

19.      On the termination of this Agreement (howsoever caused):

         (a)      Bioanalysis shall forthwith cease all further development
manufacture and sale of the licensed products except only that Bioanalysis may
sell its stock of the licensed products manufactured prior to such termination
and may fulfil any contract for the sale of these licensed products made by it
prior thereto subject to the payment of royalties to WNSM as provided under this
Agreement in respect of sales of licensed products by it or any of its
sub-licensees

         (b)      Bioanalysis shall Forthwith return to WNSM all written
information drawings specifications data and material supplied by WNSM pursuant
to this Agreement and all copies thereof and shall make no further use
whatsoever of any information so supplied;

         (c)      all rights and obligations under this Agreement and all
licences granted pursuant thereto shall automatically terminate with the
exception of:-

                  (i)      such rights of action as shall have accrued prior to
termination (including but not limited to any and all claims for any breach of
any term or undertaking contained in this Agreement ) and

                  (ii)     all obligations of Bioanalysis under this Agreement
which are expressed to survive its termination and continue thereafter

20.      This Agreement contains the entire agreement and understanding of the
parties with respect to its subject matter and supersedes all prior agreements
written or oral with respect thereto

21.      This Agreement shall not be construed as constituting Bioanalysis an
agent or employee or partner of WNSM for any purpose whatsoever and neither
party shall have the right or

                                       4.
<PAGE>

authority to act for or to bind the other party in any way or to make or give
any representation or warranty on behalf of the other or to settle any claims by
or against the other

22.      Neither of the parties hereto shall be liable in damages or have the
right to terminate for any delay or default in performance of the other
hereunder if such delay or default is caused by conditions beyond the control of
the parties hereto including but not limited to Government restrictions
including domestic or international problems such as wars insurrections strikes
fires floods work stoppages embargos and or lack of materials; provided however
that either party shall have the right to terminate this Agreement summarily by
notice if the inability of the other to perform according to the obligations of
this Agreement due to any of the above mentioned causes continues for a period
of six months

23.      All disputes differences or questions arising out of this Agreement as
to the rights and liabilities of the parties hereto or as to the interpretation
hereof shall be referring to the decision of a single arbitrator to be agreed
between the parties or in default of agreement appointed at the request of
either party by the president for the time being of the Chartered Institute of
Arbitrators Arbitration shall take place in London or in such other place as
shall be agreed between the parties

24.      Any provision of this Agreement which in any way contravenes the law of
any territory in which this Agreement takes effect shall in such territory to
the extent of such contravention be deemed severable and of no effect but the
other provisions of this Agreement shall continue in full force and effect

25.      Any notice or other document to be given under this Agreement shall be
in writing and shall be deemed duly given if left at or forwarded by registered
post or recorded delivery to the address of such party at its last known address
or in the case of Bioanalysis to its registered office and every notice or other
document shall be deemed to have been duly received and given at the time when
in the ordinary course of transmission it should have been delivered at the
address to which it was sent In proving the giving of notice it shall be
sufficient to prove that the notice was left or that the envelope containing
such notice was properly addressed and posted (as the case may be)

26.      This Agreement shall be governed by and interpreted in accordance with
the laws of England and Wales and the parties submit to the jurisdiction of the
High Court of Justice in England and Wales

         IN WITNESS WHEREOF this Agreement has been duly executed the day and
year first above written.

                                       5.

<PAGE>

                                  THE SCHEDULE

                                     PART I

                     PARTICULARS OF PATENTS GRANTED TO WNSM

<TABLE>
<CAPTION>
                                             APPLICATION OR PATENT
  CASE NO.     SHORT TITLE      COUNTRY             NUMBER             STATUS
  --------     -----------      -------             ------             ------
<S>            <C>            <C>            <C>                     <C>
[...***...]    [...***...]    [...***...]         [...***...]        [...***...]
[...***...]    [...***...]    [...***...]         [...***...]        [...***...]
[...***...]    [...***...]    [...***...]         [...***...]        [...***...]
[...***...]    [...***...]    [...***...]         [...***...]        [...***...]
[...***...]    [...***...]    [...***...]         [...***...]        [...***...]
</TABLE>

                                     PART II

                   PARTICULARS OF PATENTS APPLIED FOR BY WNSM

<TABLE>
<CAPTION>
                                             APPLICATION OR PATENT
  CASE NO.     SHORT TITLE      COUNTRY             NUMBER             STATUS
  --------     -----------      -------             ------             ------
<S>            <C>            <C>            <C>                     <C>
[...***...]    [...***...]    [...***...]         [...***...]        [...***...]
[...***...]    [...***...]    [...***...]         [...***...]        [...***...]
[...***...]    [...***...]    [...***...]         [...***...]        [...***...]
[...***...]    [...***...]    [...***...]         [...***...]        [...***...]
[...***...]    [...***...]    [...***...]         [...***...]        [...***...]
[...***...]    [...***...]    [...***...]         [...***...]        [...***...]
[...***...]    [...***...]    [...***...]         [...***...]        [...***...]
[...***...]    [...***...]    [...***...]         [...***...]        [...***...]
[...***...]    [...***...]    [...***...]         [...***...]        [...***...]
[...***...]    [...***...]    [...***...]         [...***...]        [...***...]
[...***...]    [...***...]    [...***...]         [...***...]        [...***...]
</TABLE>

                                               *CONFIDENTIAL TREATMENT REQUESTED

                                       6.

<PAGE>

THE SEAL of THE WELSH         )
NATIONAL SCHOOL OF            )
MEDICINE was hereunto         )
affixed in the presence of    )

            LS                           C.C. Banham
                                     -------------------------------------------
                                        Member of Council

                                        A.W. Roberts
                                     -------------------------------------------
                                        Registrar and Secretary

THE COMMON SEAL of            )
BIOANALYSIS LIMITED was       )
hereunto affixed in the       )
presence of: -                )

                                        John Burke
                                     -------------------------------------------
                                        Director

            LS

                                        V. Morgan
                                     -------------------------------------------
                                        Secretary

                                       7.<PAGE>

                                                                   EXHIBIT 10.31

                                            ***TEXT OMITTED AND FILED SEPARATELY
                                                CONFIDENTIAL TREATMENT REQUESTED
                                           UNDER 17 C.F.R. SECTIONS 200.80(b)(4)
                                                                   AND 240.24B-2

Date: 12TH JULY 1990

Parties:

1.       "The Licensor" : UNIVERSITY OF WALES COLLEGE OF MEDICINE whose
principal office is at Heath Park Cardiff Wales CF4 4XN

2.       "The Licensee": MOLECULAR LIGHT TECHNOLOGY LIMITED [an English Company]
whose registered office is at 31-33 Newport Road Cardiff CF2 1TQ

                                    RECITALS

         A.       The Licensor has developed and is the beneficial owner of a
substantial body of valuable Technical Information as defined below relating to
the measurement of analytes based upon the phenomenon of chemiluminescence which
is applicable to immunoassay binding protein and other assay systems and is the
beneficial owner of the Patent Rights relating thereto as defined below.

         B.       The said Technical Information has already been sub-licensed
by Bioanalysis by two Agreements one dated the 6th December 1984 in favour of
Corning Glass Works and the other dated 21st January 1986 in favour of GenProbe
Inc for particular uses only ["the excluded uses"].

         C.       The Licensee wishes to receive and the Licensor is willing to
grant a licence on the terms and conditions hereinafter set forth to use such
information and to work under the said Patent Rights in order to manufacture,
use, sell or otherwise deal in the said chemiluminescence technology save and
except the excluded uses.

                              OPERATIVE PROVISIONS

1.       DEFINITIONS

         1.1      In this Agreement the following terms shall have the following
meanings unless the context otherwise requires:

         "COPYRIGHT" All copyright and rights in the nature of copyright to
which either party may now be or may subsequently become entitled in or in
respect of all drawings and other

                                       1.
<PAGE>

documents recordings in any form and all other articles bearing or embodying any
part of the Technical Information.

         "EFFECTIVE DATE" 1st January 1990

         "IMPROVEMENTS" all improvements modifications or adaptations to any
part of the Technical Information which might reasonably be of commercial
interest to either party in the design manufacture or supply of the Products or
in the operation of the Process and which may be made or acquired by either
party during the term of this Agreement.

         "INVENTORS"

         "NET SALES VALUE" The invoiced ex-works sales value of the Products in
an arm's length transaction exclusively for money after deduction of normal
trade discounts actually granted and of any credits actually given by the
Licensee for returned or defective goods and excluding or making proper
deductions for any costs of packing insurance carriage and freight and Value
Added Tax or other sales tax and in the case of export orders any import duties
or similar applicable governmental levies or export insurance costs subject in
all cases to the same being separately charged on customer invoices. In any sale
or other disposal of any Products or part thereof otherwise than in any arm's
length transaction exclusively for money the fair-market price [if higher] in
the relevant country of disposal shall be substituted for the Net Sales Value.

         "PATENT RIGHTS" (i) the patent and applications short particulars
whereof are set out in Schedule A hereto; (ii) all patent applications that may
hereafter be filed in the Territory by or on behalf of the Licensor which either
are based on or claim priority from any of the foregoing patents and
applications or which are in respect of any Improvements to which either party
is exclusively entitled; and (iii) all patents which may be granted pursuant to
any of the foregoing patent applications.

         "PROCESS" the chemiluminescence technology referred to in recital A
above and defined in the Patent Rights.

         "PRODUCTS" clinical diagnostic kits and/or components thereof and/or
any other products incorporating the Process.

                                       2.

<PAGE>

         "TECHNICAL INFORMATION" All know-how experience drawings designs
circuit diagrams computer programs and all other technical information relating
to the Products or the Process and which might reasonably be of commercial
interest to either party in the design manufacture or supply of the Products or
in the operation of the Process.

         "TERRITORY" the World

2.       TECHNICAL INFORMATION

         2.1      If the Licensee requires additional assistance the Licensor
will use its best endeavours to provide it but accepts no further obligation in
this respect. Any additional assistance so given shall be charged to the
Licensee at the rate of (pound)500 sterling for each day of 8 working hours [and
pro rata for any part day] that each member of the Licensor's staff is so
engaged [including traveling time] plus all disbursements on travel and
subsistence reasonably incurred together with the cost to the Licensor of
providing them with such insurance cover as the Licensor may reasonably consider
appropriate. All payment under this clause shall be made monthly in arrears in
United Kingdom pounds sterling to the credit of such bank account as is
designated in writing by the Licensor.

         2.2      The Licensor warrants that all Technical Information disclosed
or to be disclosed to the Licensee hereunder is or will be to the best of the
Licensor's knowledge and belief accurate [provided always that the Licensor will
promptly correct any significant errors in the Technical Information
subsequently discovered by the Licensor] but subject thereto the Licensor shall
be under no further liability to the Licensee in respect of the Technical
Information or of the manufacture use sale or other disposition of the Process
or Products.

         2.3      The Licensee shall be exclusively responsible for the
technical and commercial operation of the Process and for incorporating any
modifications or developments thereto that might be necessary or desirable and
for all Products sold or supplied by the Licensee and accordingly the Licensee
shall indemnify the Licensor in respect of all costs damages and expenses
incurred as a result of any claims by third parties in tort or otherwise against
the Licensor arising in any way out of the use of any of the Technical
Information by the Licensee.

                                       3.

<PAGE>

         2.4      The Licensee undertakes that for so long as any part of the
Technical Information remains subject to the obligations of confidence of clause
4 hereof it will not use the same for any purpose except as expressly licensed
hereby and in accordance with the terms of this Agreement.

3.       IMPROVEMENTS

         3.1      Each party shall forthwith disclose to the other in confidence
and in such detail as that other may reasonably require all Improvements that it
may develop or acquire except insofar as such disclosure would disclose
information derived from and subject to confidentiality obligations in favour of
a third party.

         3.2      Improvements that the Licensor is due to disclose to the
Licensee under clause 3.1 above shall be deemed to be part of the Technical
Information for the purposes of the rights granted to the Licensee under clause
5 hereof.

         3.3      Save as otherwise provided herein Improvements arising from
work carried out by the Licensor alone the Licensee alone or both parties
jointly shall be the property of the Licensor.

         3.4      The Licensee shall have the irrevocable right to use such
Improvements and to the extent necessary for such use a licence relating thereto
including the right to grant sub-licences thereunder save as otherwise provided
by clause 9.6 hereof. The Licensor hereby undertakes that on request it will
confirm to any prospective sub-licensee the right of the Licensee pursuant to
this paragraph to grant such a sub-licence

4.       CONFIDENTIALITY

         4.1      Each party agrees to maintain secret and confidential all
Technical Information obtained from the other both pursuant to this Agreement
and prior to and in contemplation of it and all other information that it may
acquire from the other in the course of this Agreement to respect the other's
proprietary rights therein to use the same exclusively for the purposes of this
Agreement and to disclose the same only to those of its employees and
contractors and sub-

                                       4.
<PAGE>

licensees pursuant to this Agreement [if any] to whom and to the extent that
such disclosure is reasonably necessary for the purpose of this Agreement.

         4.2      The foregoing obligations of clause 4.1 above shall not apply
to Technical Information or other information which:

                  4.2.1    prior to receipt thereof from one party was in the
possession of the other and at its free disposal;

                  4.2.2    is subsequently disclosed to the recipient party
without any obligations of confidence by a third party who has not derived it
directly or indirectly from the other;

                  4.2.3    is or becomes generally available to the public
through no act or default of the recipient party or its agents or employees.

         4.3      Notwithstanding the foregoing provisions the parties and any
sub-licensees pursuant to this Agreement shall been entitled to disclose
Technical Information of the other to actual or potential customers for Products
insofar as such disclosure is reasonably necessary to promote the sale or use of
Products.

         4.4      Each party shall procure that all its employees contractors
and sub-licensees pursuant to this Agreement [if any] who have access to any
information of the other to which the obligations of clause 4.1 apply shall be
made aware of and subject to these obligations and shall further procure that so
far as is reasonably practicable all of such employees contractors and
sub-licensees shall enter into written undertakings in favour of the other party
to this end in a form previously approved by the Licensor.

5.       GRANT OF RIGHTS

         5.1      The Licensor hereby grants to the Licensee :

                  5.1.1    an exclusive licence to use the Technical Information
and under the Licensor's copyright to use the Process to manufacture Products;
and

                                       5.

<PAGE>

                  5.1.2    an exclusive licence to use sell or otherwise deal in
Products manufactured under the licence of clause 5.1.1 anywhere in the
Territory.

         5.2      The Licensor hereby agrees to grant to the Licensee:

                  5.2.1    an exclusive licence under the Patent Rights to use
the Process to manufacture Products; and

                  5.2.2    an exclusive licence to use sell or otherwise deal in
Products manufactured under the licence of clause 5.2.1 anywhere in the
Territory.

         5.3      Provided always that the Licensee cannot use the Technical
Information the Process and/or the Products for any of the excluded uses.

         5.4      The Licensee shall further be entitled to a licence under the
Patent Rights so far as the same extend to any act of the Licensee licensed
under clause 5.1 above.

         5.5      The parties hereto agree to execute a formal licence agreement
substantially as set out in Schedule B hereto for the purposes of registering
any patent licence granted pursuant to clause 5.4 above

         5.6      The Licensee shall with the prior consent in writing of the
Licensor be entitled to sub-licence any of the rights hereby granted with a view
to the commercial exploitation of the Process provided that the Licensee shall
remain responsible for all acts and omissions of such sub-licensees as though
they were by the Licensee. The Licensee shall forthwith deliver a copy to the
Licensor of any sub-licence granted pursuant to this clause.

         5.7      For the avoidance of doubt it is hereby declared that the
Licensee shall have no right hereunder to manufacture use or sell the Products
or to use the Process otherwise than as expressly licensed to the Licensee
hereby.

                                       6.

<PAGE>

6.       PAYMENT

         6.1      Subject to clause 6.6 below the Licensee shall during the
continuance of this Agreement pay to the Licensor the following percentages of
the Royalties or other payments received by the Licensee [or any part thereof]
namely:

<TABLE>
<S>                       <C>                  <C>                <C>
First [...***...]         Next [...***...]     Next [...***...]   Remainder of Royalties

thereof                   thereof              thereof

[...***...]               [...***...]          [...***...]        [...***...]
</TABLE>

         6.2      The Licensee shall during the continuance of this Agreement
pay to the Licensor a royalty of [...***...] of the Net Sales Value of all
Products [or any part thereof] manufactured by the Licensee and sold or
otherwise supplied for money or money's worth. In the event that the Licensee is
obliged to pay a royalty to a third party to develop use manufacture have
manufactured market or sell Products the Licensee may reduce its payment
obligation hereunder by an amount equal to the royalty to the third party but in
any event the royalty payment to the Licensor shall not be less than [...***...]
of the Net Sales Value.

         6.3      If any Products are incorporated in any other equipment or
apparatus sold by the Licensee or any sub-licensee hereunder at a price which is
included in the price for the other equipment or apparatus the Net Sales Value
for the purpose of calculating royalties due hereunder shall be that proportion
of the Net Sales Value of that other equipment or apparatus which is fairly
attributable to such Products comparing the manufacturing cost of the other
equipment or apparatus to that of the Products as components thereof.

         6.4

                  6.4.1    Payment under clause 6.1 shall be made within
[...***...] of the receipt of the royalties or other payments by the Licensee

                  6.4.2    Payment under clause 6.2 shall be made within
[...***...] of the end of each calendar quarter in respect of sales invoiced in
that calendar quarter.

                                               *CONFIDENTIAL TREATMENT REQUESTED

                                       7.

<PAGE>

         6.5      At the expiration of a period of three years from the date
hereof the relative proportion of the royalties due to each of the parties shall
be reviewed by agreement in order to achieve a more equitable distribution
subject always to the minimum royalty requirements of the Licensor mentioned in
clause 6.6 below and to a maximum royalty requirement in any one year of
[...***...].

         6.6      If the royalties payable under clauses 6.1 and 6.2 are less
than [...***...] in the [...***...] of this Agreement [...***...] in the
[...***...] of this Agreement and [...***...] in the [...***...] of this
Agreement calculated for the [...***...] from the [...***...] the Licensee shall
pay the difference between those respective sums and the royalty due under
clauses 6.1 and 6.2 within 90 days of the end of the year concerned failing
which the Licensor shall be entitled to terminate all the licences hereunder.

         6.7      All sums due under this Agreement:

                  6.7.1    are exclusive of any Value Added Tax which shall be
payable in addition on the rendering by the Licensor of any appropriate Value
Added Tax invoice;

                  6.7.2    shall be made in U.K. currency to the credit of a
bank account to be designated in writing by the Licensor. Conversion into U.K.
currency shall be calculated:

                           6.7.2.1 in the case of each royalty payment at the
rate of exchange ruling on the date the royalty payments are received

                           6.7.2.2 in the case of all other payments at the rate
of exchange ruling on the day payment is made or due whichever is earlier;

                           provided always that where any payment is made after
                           the date provided therefor herein conversion shall be
                           at the rate ruling at the date of payment if this is
                           more favour able to the Licensor :

                  6.7.3    shall be made in full without deduction of taxes
charges and other duties that may be imposed except insofar as any such
deduction may be credited in full by the Licensor against the Licensor's own tax
liabilities . The parties agree to cooperate in all respects necessary to take
advantage of such double taxation agreements as may be available.

                                               *CONFIDENTIAL TREATMENT REQUESTED

                                       8.

<PAGE>

7.       RECORDS AND REPORTS

         7.1      The Licensee agrees to keep true and accurate records and
books of account containing all data necessary for the determination of
royalties payable under clauses 6.1 and 6.2 which records and books of account
shall upon reasonable notice of the Licensor be open at all reasonable times
during business hours for inspection by the Licensor or its duly authorised
agent for the purpose of verifying the accuracy of the Licensees reports
hereunder. Copies may be taken of the records and books of account containing
such information as properly should have been contained in any statement
required to be furnished by the Licensee to the Licensor. The Licensor shall be
solely responsible for the costs of such verification unless any reports are
inaccurate in any material respect in which event the Licensee shall reimburse
the Licensor for all his costs.

         7.2      The Licensee shall submit to the Licensor within 30 days of
the end of each calendar quarter a statement setting forth with respect to the
operations of the Licensee hereunder during that period the quantity of Products
made used or sold and the Net Sales Value of Products.

         7.3      The Licensor agrees to maintain confidential all financial
information received with respect to the Licensee's operations pursuant to the
foregoing clauses 7.1 and 7.2.

8.       PERFORMANCE

         8.1      During the continuance of this Agreement the Licensee shall:

                  8.1.1    use its best endeavours to promote the distribution
and sale of Products in the Territory as widely as its resources reasonably
permit and will make available all necessary selling and manufacturing
facilities to meet in full all demands for Products throughout the Territory.
The Licensee shall seek to maximise such demand consistent only with the
Licensee obtaining a reasonable rate of return on its assets employed in making
and selling Products;

                  8.1.2    ensure that all Products supplied by the Licensee
meet all such reasonable specifications as the Licensor may from time to time
apply thereto and satisfy in performance quality construction and use the
reasonable requirements of the Licensor and shall upon

                                       9.

<PAGE>

reasonable notice from the Licensor give the Licensor or its authorised
representative free access at any reasonable time to the premises of the
Licensee for the purpose of ensuring that the Licensee is observing these
obligations;

                  8.1.3    sell Products to any suitable buyer independently of
any other products of the Licensee if so required;

                  8.1.4    ensure that all literature prepared by the Licensee
and relating to Products bears an acknowledgment to the effect that they are
subject to a licence from the Licensor and attach to all Products a label
quoting relevant patent numbers and stating that such Products are made under
licence from the Licensor;

                  8.1.5    include in the terms and conditions of sale or other
supply of the Products a guarantee to the effect that the Licensee will during
at least the period of 12 months from the date of such sale or supply replace at
its own expense and free of charge any Products supplied by it that are
defective by reason of faulty manufacture or through in adequate workmanship or
materials;

                  8.1.6    provide adequate servicing facilities for any
Products manufactured and/or supplied by the Licensee;

                  8.1.7    not act as agent of the Licensor and specifically not
give any indication that it is acting otherwise than as principal and in
advertising or selling Products not make any representation or give any warranty
on behalf of the Licensor.

         8.2      The Licensee shall not during the continuance of the Agreement
and for a period of 5 years from the date of its termination for any reason or
until expiry of any relevant Patent Rights [whichever is the sooner] be directly
or in directly concerned in the manufacture distribution sale or other supply in
any part of the Territory of any manufactured goods which by reason of their
properties and performance are commercially competitive with any Products.

         8.3      The Licensee shall at its own expense register or procure the
registration of any licence agreement executed under clause 5.5 hereof.

                                      10.

<PAGE>

9.       PATENTS

         9.1      The Licensor shall at its own cost diligently prosecute to
grant all subsisting Worldwide patent applications within the Patent Rights so
as to secure the broadest monopoly reasonably obtainable consistent with
avoiding serious prejudice to the validity of such granted patents and shall
maintain all Worldwide patents within the Patent Rights in force for the full
terms thereof.

         9.2      In the event of any infringement by a third party of any of
the Patent Rights in the Territory on such a scale as to affect prejudicially
the Licensee's business in the Products to a substantial extent the Licensee may
take all legitimate steps to halt such infringement. Subject to receiving advice
from experienced Patent Counsel that infringement proceedings including any
interlocutory proceedings where relevant stand a reasonable chance of success
the Licensee may request the Licensor to lend its name to such proceedings and
provide reasonable assistance and the Licensor will do so subject to the
Licensee giving it an indemnity in respect of all costs damages and expenses
that it may incur including any award of costs against it insofar as the
aggregate of all such costs and damages may exceed that recoverable under the
next following provisions. Where such infringement proceedings are conducted by
the Licensee under the name of the Licensor the Licensee may apply all royalties
due under clauses 6.1 and 6.2 hereof subsequent to the date of notification by
the Licensee to the Licensor of the relevant infringement to defray any costs
directly incurred by the Licensee [excluding award of costs in favour of third
parties] provided however that the total liabilities or waiver of royalties of
the Licensor hereunder shall in no circumstances exceed the sum of all royalties
due subsequent to that date and up to the date of the delivery of the final
decision in the relevant infringement proceedings and provided further that this
provision shall only apply subject to the Licensee exercising all due diligence
in pursuing the proceedings to a conclusion. Any damages recovered shall be
dealt with in a manner which shall be fair and reasonable as between the
Licensor and the Licensee.

         9.3      To the best of the Licensor's knowledge and belief the
exercise of the rights granted or to be granted to the Licensee hereunder will
not result in the infringement of valid patents of third parties. Subject
thereto the Licensor gives no warranty in this respect and does

                                      11.

<PAGE>

not give the Licensee any indemnity against costs damages expenses or royalties
arising out of proceedings brought against the Licensee or any customer of the
Licensee by any third party. Should the Licensee be sued for infringement of any
patent or patents of the third party by reason of its operation of the Process
or manufacture use or sale of the Products the Licensor shall on request assist
the Licensee in its defence to such action to the extent that in all the
circumstances it is reasonable to do so but shall otherwise be under no
obligations in respect thereof. All costs of any such action shall be borne by
the Licensee to whom shall belong all sums that may be recovered from the third
party.

         9.4      If at any time during this Agreement the Licensee directly or
indirectly opposes or assists any third party to oppose the grant of letters
patent on any patent application within the patent rights or disputes or
directly or in directly assists any third party to dispute the validity of any
patent within the patent Rights or any of the claims thereof the Licensor shall
be entitled at any time thereafter to determine all or any of the licences
granted hereunder forthwith by notice thereof to the Licensee.

         9.5      The Licensor may at any time in respect of an Improvement
elect not to pursue further an application for patent protection or to maintain
any such patent protection as it may have obtained in which event the Licensor
shall notify the Licensee and shall if so requested assign all rights it may
have therein to the Licensee provided that the Licensor shall be entitled to a
full irrevocable licence under all relevant rights.

         9.6      Subject to the foregoing each party shall be free to apply for
patent protection for any invention not made in whole or in part by an employee
of the other provided however that the specification in support thereof does not
disclose any confidential information of the other.

         9.7      The Licensee shall on demand from the Licensor contribute one
half of the costs incurred by the Licensor in maintaining in force any of the
patent rights or applying for further patents.

                                      12.

<PAGE>

10.      TERM AND TERMINATION

         10.1     Subject as hereinafter provided and clause 6.6 this Agreement
shall continue in force in each country of the Territory until expiry of the
last to expire of the patent rights in such country unless earlier terminated in
accordance with the following provisions of this clause.

         10.2     If either party is in breach of any obligation on it hereunder
and in the case of a breach capable of remedy it shall not have been remedied by
the defaulting party within 30 days of written notice specifying the breach and
requiring its remedy or if the Licensee becomes insolvent has a receiver
appointed over the whole or any part of its assets enters into any compound with
creditors or has an order made or resolution passed for it to be wound up
[otherwise than in furtherance of a scheme for amalgamation or reconstruction]
or if the ownership or control of the Licensee shall pass into the hands of any
legal person which the Licensor in its reasonable discretion considers
unsuitable for any reason whatsoever then the Licensor or in the case of breach
the party not in breach of the obligation or condition may forth with terminate
this Agreement by notice without prejudice to the accrued rights of either
Party.

         10.3     Termination of this Agreement for any reason shall not bring
to an end:

                  10.3.1   the secrecy obligations on the parties hereto;

                  10.3.2   the Licensee's obligations to pay royalties or other
sums which have accrued due or which will become due in respect of sales under
clause 10.4;

                  10.3.3   the obligations [if any] on the Licensee under clause
10.5;

                  10.3.4   the licences [ if any] under clauses 3.3, 3.5 and 9.6

         10.4     On termination of this Agreement for any reason the Licensee
shall continue to have the right to complete deliveries on contracts in force at
the date and to dispose of Products already manufactured subject to payment to
the Licensor of royalties thereon in accordance with clause 6 above.

         10.5     On termination of this Agreement for any reason under clause
10.2 above the Licensee shall offer to the Licensor at cost all stocks of
Products and promotional and other

                                      13.
<PAGE>

literature relating thereto in its possession or control and shall provide the
Licensor with all reasonable facilities to inspect the same and shall deliver up
to the Licensor all production manuals and all other documents [including copies
thereof] in its possession or control containing Technical Information remaining
subject to the secrecy obligations of clause 4 hereof.

11.      FORCE MAJEURE

         11.1     If either party to this Agreement is prevented or delayed in
the performance of any of its obligations under this Agreement by force majeure
and if such party gives written notice thereof to the other party specifying the
matters constituting force majeure together with such evidence as it reasonably
can give and specifying the period for which it is estimated that such
prevention or delay will continue then the party in question shall be excused
the performance or the punctual performance as the case may be as from the date
of such notice for so long as such cause of prevention or delay shall continue.

         11.2     For the purpose of this Agreement "force majeure" shall be
deemed to be any cause affecting the performance of this Agreement arising from
or attributable to acts events omissions or accidents beyond the reasonable
control of the party to perform and without limiting the generality thereof
shall include the following:

                  11.2.1   strikes lock-outs or other industrial action;

                  11.2.2   civil commotion riot invasion war threat or
preparation for war:

                  11.2.3   fire explosion storm flood earthquake subsidence
epidemic or other natural physical disaster;

                  11.2.4   impossibility of the use of railways shipping
aircraft motor transport or other means of public or private transport:

                  11.2.5   political interference with the normal operations of
any party

                                      14.

<PAGE>

12.      GENERAL

         12.1     This Agreement shall be binding upon and enure to the benefit
of the parties hereto and the irrespective legal successors but shall not
otherwise be assignable by the Licensee without the written consent of the
Licensor which consent shall not be unreasonably withheld.

         12.2     No variation or amendment of this Agreement shall bind either
party unless made in writing in the English language and agreed to in writing by
duly authorised officers of both parties.

         12.3     If any provision of this Agreement is agreed by the parties to
be illegal void or unenforceable under any law that is applicable hereto or if
any Court of competent jurisdiction in a final decision so determines this
Agreement shall continue in force save that such provision shall be deemed to be
excised herefrom with effect from the date of such agreement or decision or such
earlier date as the parties may agree.

         12.4     The headings in this Agreement are for convenience only and
are not intended to have any legal effect.

         12.5     A failure by either party hereto to exercise or enforce any
rights conferred upon it by this Agreement shall not be deemed to be a waiver of
any such rights or operate so as to bar the exercise or enforcement thereof at
any subsequent time or times.

13.      NOTICES

         13.1.    Any notice required to be given hereunder by either party to
the other shall be in writing and shall be served by sending the same by
registered or recorded delivery post to the address of the other party as given
herein or to such other address as that party may have previously notified to
the party giving notice as its address for such service.

         13.2.    All notices documents communications and any other data to be
provided under this Agreement shall be in the English language unless otherwise
agreed

                                      15.

<PAGE>

14.      GOVERNING LAW AND DISPUTES

         14.1.    The construction validity and performance of this Agreement
shall be governed in all respects by English law

         14.2.    All disputes arising in any way out of or affecting this
Agreement shall be referred to arbitration in London under the rules of
conciliation and arbitration of the International Chamber of Commerce before a
single arbitrator whose decision shall be final

         AS WITNESS the hands of the parties hereto the day and year first
before written

                                      16.

<PAGE>

                                   SCHEDULE A

                                  PATENT RIGHTS

                         PARTICULARS OF GRANTED PATENTS

<TABLE>
<CAPTION>
  CASE NO.         SHORT TITLE        COUNTRY      PATENT NO.        STATUS      RENEWALS DUE
  --------         -----------        -------      ----------        ------      ------------
<S>                <C>              <C>           <C>              <C>            <C>
[...***...]        [...***...]      [...***...]   [...***...]      [...***...]    [...***...]
[...***...]        [...***...]      [...***...]   [...***...]      [...***...]    [...***...]
[...***...]        [...***...]      [...***...]   [...***...]      [...***...]    [...***...]
[...***...]        [...***...]      [...***...]   [...***...]      [...***...]    [...***...]
[...***...]        [...***...]      [...***...]   [...***...]      [...***...]    [...***...]
[...***...]        [...***...]      [...***...]   [...***...]      [...***...]    [...***...]
[...***...]        [...***...]      [...***...]   [...***...]      [...***...]    [...***...]
[...***...]        [...***...]      [...***...]   [...***...]      [...***...]    [...***...]
[...***...]        [...***...]      [...***...]   [...***...]      [...***...]    [...***...]
[...***...]        [...***...]      [...***...]   [...***...]      [...***...]    [...***...]
                                                  [...***...]
[...***...]        [...***...]      [...***...]   [...***...]      [...***...]    [...***...]
[...***...]        [...***...]      [...***...]   [...***...]      [...***...]    [...***...]
[...***...]        [...***...]      [...***...]   [...***...]      [...***...]    [...***...]
</TABLE>

                       PARTICULARS OF PENDING APPLICATIONS

<TABLE>
<CAPTION>
  CASE NO.         SHORT TITLE        COUNTRY     PATENT NO.         STATUS
  --------         -----------        -------     ----------         ------
<S>                <C>              <C>           <C>              <C>
[...***...]        [...***...]      [...***...]   [...***...]      [...***...]
[...***...]        [...***...]      [...***...]   [...***...]      [...***...]
[...***...]        [...***...]      [...***...]   [...***...]      [...***...]
</TABLE>

                                               *CONFIDENTIAL TREATMENT REQUESTED

                                      17.

<PAGE>

                                   SCHEDULE B

                     FORMAL PATENT LICENCE FOR REGISTRATION

Date:                       1990
Parties:
1.       "The Licensor" :
2.       "The Licensee" :

Recitals:

[A] The Licensor is the registered proprietor of United Kingdom Patent No.
for an invention entitled
[B] By an Agreement dated the             day of            199
it was agreed between the parties thereto for the consideration therein
mentioned that the Licensor would grant to the Licensee [an exclusive] [a
non-exclusive] licence under the said Patent as herein set forth

[C] This Licence is granted in pursuance of the said Agreement and not in
substitution therefor whereby nothing herein contained shall in any way derogate
from the said Agreement which shall remain in full force and effect

Operative provision:

Pursuant to the said Agreement the Licensor hereby grants [and shall from the
date of the publication of the application for the said Patent be deemed to have
granted] to the Licensee [exclusive] [a non-exclusive] authority and licence to
manufacture use exercise and sell the said invention and to do all other things
within the scope of protection of the said Patent on the terms and conditions of
the said Agreement whilst the said Patent shall remain in force unless this
Licence shall be terminated prior thereto under provisions of the said Agreement
or unless the said Agreement shall itself be terminated whereupon this Licence
shall ipso facto terminate

IN WITNESS whereof the parties hereto have executed this licence the day and
year first above written

                                      B-1.

<PAGE>

THE COMMON SEAL of the Licensor          [SEAL of University of Wales College of
                                         Medicine]
Was hereunto affixed in the presence of:

                           Director

                           Secretary

THE COMMON SEAL of the Licensee          [SEAL of Molecular Light Technology
                                         Limited]
was hereunto affixed in the presence of:

                           Director

                           Secretary

SIGNED by                  /s/ Herbert Dutche
on behalf of the Licensor
in the presence of :-

SIGNED by                  /s/ James Stuart Woodhead
on behalf of the Licensee
in the presence of :-

                                      B-2.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00061-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00061-of-00352.parquet"}]]